Phosphorylation of steroid receptor coactivator-3 (SRC-3) at serine 857 is regulated by the p38MAPK-MK2 axis and affects NF-κB-mediated transcription

Shrestha, Anup; Bruckmueller, Henrike; Kildalsen, Hanne; Kaur, Gurjit; Gaestel, Matthias; Wetting, Hilde Ljones; Mikkola, Ingvild; Seternes, Ole-Morten

doi:10.1038/s41598-020-68219-4

Download PDF

Article
Open access
Published: 09 July 2020

Phosphorylation of steroid receptor coactivator-3 (SRC-3) at serine 857 is regulated by the p38^MAPK-MK2 axis and affects NF-κB-mediated transcription

Anup Shrestha¹,
Henrike Bruckmueller^1,2,
Hanne Kildalsen¹,
Gurjit Kaur¹,
Matthias Gaestel³,
Hilde Ljones Wetting¹,
Ingvild Mikkola¹ &
…
Ole-Morten Seternes¹

Scientific Reports volume 10, Article number: 11388 (2020) Cite this article

2843 Accesses
12 Citations
2 Altmetric
Metrics details

Subjects

Abstract

Steroid receptor coactivator-3 (SRC-3) regulates the activity of both nuclear hormone receptors and a number of key transcription factors. It is implicated in the regulation of cell proliferation, inflammation and in the progression of several common cancers including breast, colorectal and lung tumors. Phosphorylation is an important regulatory event controlling the activities of SRC-3. Serine 857 is the most studied phospho-acceptor site, and its modification has been reported to be important for SRC-3-dependent tumor progression. In this study, we show that the stress-responsive p38^MAPK-MK2 signaling pathway controls the phosphorylation of SRC-3 at S857 in a wide range of human cancer cells. Activation of the p38^MAPK-MK2 pathway results in the nuclear translocation of SRC-3, where it contributes to the transactivation of NF-kB and thus regulation of IL-6 transcription. The identification of the p38^MAPK-MK2 signaling axis as a key regulator of SRC-3 phosphorylation and activity opens up new possibilities for the development and testing of novel therapeutic strategies to control both proliferative and metastatic tumor growth.

Serine residues 726 and 780 have nonredundant roles regulating STAT5a activity in luminal breast cancer

Article Open access 29 June 2021

SRSF1 promotes the inclusion of exon 3 of SRA1 and the invasion of hepatocellular carcinoma cells by interacting with exon 3 of SRA1pre-mRNA

Article Open access 19 May 2021

An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy

Article Open access 13 May 2019

Introduction

The steroid receptor coactivator 3 (SRC-3) is a transcriptional coactivator of the p160 family encoded by the gene nuclear receptor coactivator 3 (NCOA3). It was originally identified as a coactivator for nuclear receptors¹, but is now recognized as a coactivator of several other transcription factors including E2F transcription factor 1 (E2F1)², polyomavirus enhancer activator 3 (PEA3)³, activator protein-1 (AP-1)^4,5, and nuclear factor-κB (NF-κB)^6,7. Based on this broad spectrum of transcriptional activities, SRC-3 has been shown to play important roles in a wide range of physiological processes, such as cell proliferation, cell survival, mammary gland development⁸ and metabolism⁹. Since 1997, when SRC-3 was found to be amplified in breast cancer¹⁰ its role in cancer progression has been broadly investigated. It has been shown to be implicated in hormone-related cancers, such as endometrial¹¹, ovarian¹², prostate¹³ and breast cancer¹⁴, but also in in hormone-independent cancer types such as esophageal, squamous cell, colorectal, hepatocellular, pancreatic and non-small cell lung cancer¹⁵. SRC-3 modulates various processes, for example cell proliferation¹⁶ , development of metastasis¹⁷, and resistances to anti-cancer drugs^18,19.

The function of the SRC-3 protein is highly regulated by post-transcriptional modifications through phosphorylation. SRC-3 is phosphorylated at multiple residues mediated by distinct protein kinases, suggesting that SRC-3 might be controlled by several different signaling pathways in health and disease^20,21. Among the different phosphorylation sites, the most frequently reported modification of SRC-3 is the phosphorylation at serine 857 (S857)²². This phosphorylation has been shown to be important for regulation of estrogen receptor, androgen receptor and NF-κB-mediated transcription²⁰. In addition, more recent data indicate that phosphorylation at S857 is also essential for the ability of SRC-3 to promote lung and breast cancer progression and metastasis²³. With regards to these observations, the protein kinase (or kinases) responsible for this specific phosphorylation of SRC-3 might be attractive therapeutic targets for treatment of lung and breast cancer. However, to date the identity of the protein kinases able to phosphorylate SRC-3 at S857 remains unclear. Suggested candidates include protein kinase A (PKA)²⁰, I kappa B kinase (IKK)⁷ and the metabolic enzyme 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 4 (PFKFB4)²³.

Recently, SRC-3 was also reported to be a novel target for the extracellular regulated kinase 3 (ERK3)^3,24. ERK3 is an atypical member of the Mitogen-Activated Protein Kinases (MAPKs) family of protein kinases. So far, little is known about the biological function of these atypical kinases. Our limited knowledge can partly be attributed to a lack of identified physiological substrates. The first physiological substrate identified for ERK3 was the MAPK-Activiated Protein Kinase (MAPKAPK) MK5²⁵. However, besides being a regulator and downstream substrate of ERK3 and ERK4, the biological function of MK5 is unknown. Thus, the data indicating that SRC-3 is a substrate for ERK3, could be an important step towards our understanding of the biological role of ERK3^3,24.

In the present study, we aimed to confirm that S857 of SRC-3 is a bona fide substrate for ERK3 using the purified recombinant kinase. Unexpectedly, we found that ERK3 was not able to phosphorylate SRC-3 at S857 efficiently in vitro. Instead, we observed that SRC-3 was efficiently phosphorylated at S857 by the MAPKAP kinases MK2 and MK5 in vitro. However, only MK2, a downstream effector of the activated p38^MAPK pathway, could mediate this specific phosphorylation in living cells. The phosphorylation of SRC-3 at S857 was efficiently inhibited by specific inhibitors of MK2 and MK3 in unstimulated cells and in cells with active p38^MAPK signaling. Moreover, our data demonstrate that SRC-3 is an important regulator of the inducible expression of the pro-inflammatory cytokine IL-6 in response to activation of the p38^MAPK-MK2 signaling pathway by TNF-α.

Results

SRC-3 is not a substrate of ERK3 in vitro

As SRC-3 was described as substrate for ERK3 in lung cancer cells³, we aimed to confirm this finding in an in vitro approach. First, we tested whether recombinant active ERK3 could phosphorylate a recombinant GST fusion protein encoding the CBP-interacting domain (CID) of SRC-3 (SRC-3 aa 840–1,080). As shown in Fig. 1A, recombinant active ERK3 was unable to phosphorylate the GST-CID-SRC-3 WT (wild type) fusion protein. In contrast, when MK5, a bona fide ERK3 substrate, was added to the reaction efficient phosphorylation of GST-CID-SRC-3-WT was readily observed and was also seen after incubation with activated MK5 alone (Fig. 1A). Importantly, no phosphorylation was observed when a mutant version of the protein (GST-CID-SRC-3 S857A), in which serine 857 was replaced with alanine was used as substrate (Fig. 1A). These findings indicate that SRC-3 is phosphorylated at S857 by the ERK3 downstream effector MK5 rather than by ERK3 itself.

Next, we aimed to determine if MK5 is also responsible for the phosphorylation of SRC-3 at S857 in vivo. We first generated a S857 phospho-specific SRC-3 antibody. The specificity of the antibody generated (P-S857-SCR-3 antibody) was then tested in an in vitro kinase assay by incubating GST-CID-SRC-3 WT and GST-CID-SRC-3 S857A with and without active MK5. The anti-P-S857-SRC-3 antibody specifically recognized the phosphorylation of GST-CID-SRC-3 WT at S857, while no signal was detected when incubating the mutated GST-CID-SRC-3 S857A protein (Fig. 1B). The sensitivity of the anti-P-S857-SRC-3 antibody was then determined by Western-blot analysis of a serial dilution of MK5-phosphorylated GST-CID-SRC-3 WT fusion protein revealing that the signal detected with this antibody was linear over a wide range of concentrations of phosphorylated SRC-3 (Fig. 1C). Next, we determined whether the anti-P-S857-SRC-3 antibody was able to discriminate between unphosphorylated SRC-3 and SRC-3 phosphorylated at S857 in vivo in mammalian cells. The human lung cancer cell line H1299 was transfected with expression vectors encoding either SRC-3 WT or SRC-3 S857A. Western-blot analysis confirmed the specificity of the anti-P-S857-SRC-3 antibody for the phosphorylation of S857, as a clear signal was only detected for SRC-3 WT but not for SRC-3 S857A (Fig. 1D). In a final step, we confirmed that the anit-P-S857-SRC-3 antibody could also discriminate between endogenous SRC-3 phosphorylated or unphosphorylated at S857. After immunoprecipitation of endogenous SRC-3 from extracts of H1299 cells, the precipitated SRC-3 was split into two fractions and one fraction was treated with lambda phosphatase. Western-blot analysis showed that the anti-P-S857-SRC-3 antibody detected a signal only in the untreated fraction, and not in the fraction treated with lambda phosphatase (Fig. 1E). Taken together these results clearly demonstrate both the sensitivity and the specificity of the newly generated anti-P-S857-SRC-3 antibody.

SRC-3 is phosphorylated at S857 by the MAPKAP kinases MK2 and MK5 in vitro

In the next experiments, we used the anti-P-S857-SRC-3 antibody to identify the kinase(s) that mediate the phosphorylation of SRC-3 at S857. As we could not detect any efficient phosphorylation of SRC-3 by ERK3, but only by MK5 (Fig. 1A,B), we examined the sequence surrounding serine 857 in SRC-3. This sequence (Y-N-R-A-V-S-L) is more closely related to the optimal phosphorylation site sequences for either a MAPKAPK or protein kinase A (X-R-X-X-S-L), than to recognition sequence for a proline-directed MAPK such as ERK3 (T/S-P) (Fig. 2A)²⁶. To investigate and compare the preference of MAPKAPKs and MAPKs for the S857 phosphorylation site in SRC-3 in vitro, we set up a kinase assay using the GST-CID-SRC-3 WT fusion protein as substrate. The amount of each kinase used in the assay (MAPKAPKs MK2 and MK5, and the MAPKs ERK2, ERK3 and p38α) was adjusted to give equal input of kinase activity of 0.1 units. Under these conditions, both active MK2 and MK5 phosphorylated SRC-3 at S857 efficiently, while active ERK2, ERK3 and p38α were unable to phosphorylate this residue (Fig. 2B). To further explore the dynamics of S857 phosphorylation by MK2 and MK5, in vitro kinase assays were performed in dose- (Fig. 2C) and time-dependent (Fig. 2D) manners. The results showed that phosphorylation of SRC-3 increased gradually both with increasing amounts of active MK2 and MK5 (Fig. 2C) and with increasing incubation time (Fig. 2D). Taken together, these experiments demonstrated that SRC-3-S857 is an in vitro substrate for both of MK2 and MK5.

The p38^MAPK signaling pathway controls the phosphorylation of SRC-3 at S857 in vivo

MK2 and MK5 are controlled by two different signaling pathways; while MK5 is located downstream of the atypical MAPKs ERK3 and ERK4, MK2 lies downstream of the p38^MAPK. First, we aimed to determine whether ERK3 and MK5 are required in vivo for phosphorylation of SRC-3 at S857. Therefore, we analyzed the phosphorylation status of endogenous SRC-3 at S857 in H1299 lung cancer cells, which were transfected with siRNA against MK5 or ERK3. Loss of either MK5 or ERK3 did not affect the phosphorylation state of SRC-3 at S857 in these cell extracts (Fig. 2E). These results suggest that SRC-3 is not a physiological substrate of neither ERK3 nor MK5.

As the consensus sequence around S857 in SRC-3 resembles a MAPKAPK phosphorylation motif, it is possible that other MAPKAP kinases lying downstream of the MAPK’s ERK1/2 or p38^MAPK could be responsible for the phosphorylation of this site in vivo. To investigate this, we treated the lung cancer cell line H1299 with specific kinase inhibitors before analyzing the phosphorylation state of SRC-3 at S857. Since all of the MAPKAPKs except MK5 are activated by either MAP Kinase Kinase (MKK) 1/2-ERK1/2 or MKK3/6-p38^MAPK α/β, we treated the cells with the MKK1/2 specific inhibitor PD-184352 or with the p38^MAPKα/β specific inhibitor SB-202190. As shown in Fig. 3A, inhibition of MKK1/2 activity using PD-184352 (thereby inhibiting RSKs, MSKs and MNKs activity via ERK1/2) did not affect the phosphorylation of SRC-3 at S857. However, inhibition of the p38^MAPK activity using SB-202190, and thereby inhibition of MK2/3 (and MSK1/2 and MNK1/2), profoundly inhibited the phosphorylation of SRC-3.

Based on these findings, we aimed to further validate the role of the p38^MAPK signaling pathway in the regulation of SRC-3 phosphorylation at S857. Therefore, we stimulated various cell lines with well-known p38^MAPK activators (TNF-α, anisomycin and sodium arsenite (SA)). All cell lines analyzed, namely the lung cancer cell lines H1299 (Fig. 3B) and A549 (Fig. 3C), the human embryonic kidney cell line HEK293 (Fig. 3D), the human cervical carcinoma cell line HeLa (Fig. 3E) and the human breast cancer cell line MDA MB 231 (Fig. 3F) showed an enhanced phosphorylation of SRC-3 at S857 upon exposure to the three p38^MAPK activators. In addition to this, when p38^MAPK activity was inhibited using SB-202190, the TNF-α and anisomycin-induced (Fig. 3G) and SA-induced (Fig. 3H) SRC-3 phosphorylation at S857 was not observed. Since the results were obtained by activation of the p38^MAPK signaling pathway using different types of p38^MAPK activators in several different cell lines, it indicates that the phosphorylation of SRC-3 at S857 by activation of p38^MAPK signaling is a general phenomenon.

Phosphorylation of SRC-3 at S857 is dependent on MK2

The results from in vitro kinase assays and cell culture experiments with specific inhibitors suggest MK2 as a bona fide downstream target of p38^MAPK, rather than the MAPKAPKs downstream of ERK1/2, is the kinase responsible for phosphorylation of SRC-3 at S857. To investigate this hypothesis further, we utilized mouse embryonic fibroblast (MEF) cells and bone marrow derived cells (BMDC) isolated from double knockout (DKO) mice lacking both MK2 and MK3. As the expression of both of these downstream kinases is required for p38^MAPK stability²⁷ and thus to ensure that our results reflect the loss of MK2/MK3 and not the resulting depletion of p38^MAPK, we re-expressed either wild type MK2 (MK2^WT) or a kinase dead mutant of MK2 (MK2^K72A) into the DKO cell lines. The three different cell lines (MK2/MK3^−/−; MK2/MK3^−/− + MK2^WT; MK2/MK3^−/− + MK2^K72A) were then treated with the p38^MAPK pathway activators (TNF-α, lipopolysaccharide (LPS) or sodium arsenite (SA)), and the phosphorylation status of SRC-3 at S857 was analyzed. In the MK2/MK3^−/− cells and the MK2/MK3^−/− cells expressing the kinase-dead MK2 (MK2^K72A), none of the p38^MAPK pathway stimulants resulted in induction of S857 phosphorylation. However, SA and LPS induced S857 phosphorylation in the MK2/MK3^−/− cells rescued with MK2^WT (MEF cell, Fig. 4A; BMDC cells, Fig. 4B). Overall, these results indicate that MK2 activity is required for phosphorylation of SRC-3 at S857 in murine cells.

Next, we studied the role of MK2 (and MK3) for phosphorylation of SRC-3 at S857 in different human cancer cell lines. For these experiments, we used the specific MK2 kinase inhibitor PF-3644022. A549 cells pretreated with different doses of PF-3644022 were stimulated with TNF-α (Fig. 4C) and anisomycin (Fig. 4D). Increasing doses of PF-3644022 markedly inhibited TNF-α and anisomycin-induced MK2 activity, as shown by the decrease in phosphorylation of HSP27, a known substrate of MK2²⁸. Moreover, PF-3644022 effectively prevented the phosphorylation of SRC-3 at S857 (Fig. 4C,D). Then, we used A549 cells where we knocked down endogenous SRC-3 expression with a specific siRNA, and at the same time co-transfected the cells with vectors encoding siRNA resistant FLAG-tagged SRC-3 WT or the phosphorylation site mutant SRC-3-S857A. Analysis of ectopically expressed SRC-3 revealed that activation of the p38^MAPK pathway with TNF-α or anisomycin resulted in increased phosphorylation of SRC-3 at S857, which was prevented by pre-incubation with the MK2-inhibitor PF-3644022 (Fig. 4E) (Supplementary Fig. S1A). No phosphorylation of SRC-3 was observed in the cells transfected with SRC-3-S857A. The effect of PF-3644022 on anisomycin-stimulated S857 phosphorylation was also observed for endogenous SRC-3 protein in five human cell lines: HeLa (Fig. 4F), A549 (Fig. 4G), H1299 (Fig. 4H), HEK 293 (Fig. 4I) and the breast cancer cell line MDA MB 231 (Fig. 4J). These results indicate that MK2 is responsible for phosphorylation of SRC-3 at S857 in response to activation of the p38^MAPK signaling pathway.

In the next step, we examined the dose and time dependent effect of TNF-α on MK2 activation (as indicated by phosphorylation of MK2 at T334), and the phosphorylation of SRC-3 at S857 in the breast cancer cell line MDA MB 231 and the lung cancer cell line A549. We observed that the phosphorylation of SRC-3 at S857 follows similar pattern as the activation of MK2, both in relations to dose in MDA-MB 231 cells (Fig. 5A), and time after stimulation in both MDA-MB 231 and A549 cells (Fig. 5B,C).

IKK is not involved in TNF-α induced phosphorylation of SRC-3 at S857

In unstimulated cells, the NF-κB proteins are sequestered in the cytoplasm by IκBs (Inhibitor of κB). When stimulated, IκB kinase (IKK) becomes activated and phosphorylates IκB proteins. This results in degradation of IκB and activation of NF-κB. IKK is composed of heterodimer of the catalytic IKK-α and IKK-β subunits and a regulatory subunit IKK-γ²⁹. IKK-α and IKK-β are reported to phosphorylate SRC-3 at S857²⁰. In order to investigate whether IKK is involved in p38^MAPK-MK2 signaling pathway in phosphorylation of SRC-3, we studied the role of IKK-β and IKK-α on TNF-α-induced phosphorylation of SRC-3 at S857 in A549 cells using IKK-β inhibitor, BI-605906³⁰ (Fig. 6A) and siRNA against IKK-α (Fig. 6B) respectively. We found that neither exclusive inhibition of IKK-β activity (Fig. 6A) nor the exclusive inhibition of IKK-α expression (Fig. 6B) influenced the TNF-α-induced phosphorylation of SRC-3 at S857. However, at higher concentration of BI-605906 (Fig. 6A, last lane) and mutual inhibition of IKK-β activity and IKK-α expression together (Fig. 6B, last lane), a slight decrease in the phosphorylation of SRC-3 was observed. Moreover, no effect on the TNF-α-induced phosphorylation of HSP27 was observed when IKK-β activity (Fig. 6A) and IKK-α expression (Fig. 6B) were inhibited, thereby suggesting that IKK does not influence the p38^MAPK-MK2 pathway. Based on these findings, we conclude that MK2 is the major kinase phosphorylating SRC-3 at S857 in A549 cells.

p38^MAPK and MK2 activity is important for the nuclear translocation of SRC-3

SRC-3 contains both a nuclear localization signal (NLS) and a nuclear export signal (NES)³¹, and has been demonstrated to shuttle between the nucleus and cytoplasm depending on both its phosphorylation state, and interaction with the estrogen receptor³². Having identified p38^MAPK and MK2 as crucial mediators of SRC-3 phosphorylation, we determined whether p38^MAPK and MK2 activity might also regulate subcellular distribution of SRC-3. As shown in Fig. 7A,B,E,F (left panels), immunostaining of SRC-3 in untreated A549 cells indicate abundant SRC-3 protein both in the cytosol outside the nucleus, as well as in the nucleus. Upon stimulation with TNF-α, SRC-3 translocates into the nucleus leading to almost complete nuclear localization of SRC-3. However, after pretreatment with the specific p38^MAPK inhibitor SB-202190 (Fig. 7A,E (right panels)) and the specific MK2 kinase inhibitor PF-3644022 (Fig. 7B,F (right panels)), TNF-α stimulation did not lead to a significant translocation of SRC-3 into the nucleus.

Together with the observation that SB-202190 and PF-3644022 prevented phosphorylation of SRC-3 at S857, these findings strongly suggest that phosphorylation of SRC-3 at S857 by p38^MAPK and MK2 may be important for efficient nuclear localization of SRC-3.

Since phosphorylation of SRC-3 at S857 seems to be important for TNF-α-induced nuclear translocation of SRC-3, we further wanted to study whether the mutated SRC-3 S857A is translocated into nucleus when stimulated with TNF-α. For this, we generated A549 cells where we knocked out endogenous SRC-3 using CRISPR-Cas9 mediated gene editing (Fig. 7C) (Supplementary Fig. S3). When we transfected the SRC-3^KO A549 cells with an expression vector encoding wild type SRC-3 and mutated SRC-3 S857A and stimulated with TNF-α, we found that SRC-3 WT was more efficiently translocated into nucleus than SRC-3 S857A (Fig. 7D,G). This finding further strengthens our hypothesis that phosphorylation of SRC-3 at S857 significantly enhances its nuclear translocation.

SRC-3 is required for MK2-mediated induction of IL-6 mRNA expression in response to TNF-α

After we established that the p38^MAPK-MK2 pathway is involved in phosphorylation of SRC-3 at S857, we aimed to explore the biological function of this modification. SRC-3 has been reported to co-activate NF-κB-mediated gene expression, and this was shown to depend on the phosphorylation of S857⁷. Therefore, we aimed to determine the role of S857 in regulating NF-κB-mediated transcription in A549 cells. In order to investigate this, we transfected SRC-3^KO A549 cells with a NF-κB-dependent luciferase reporter gene. A basal induction of luciferase activity in response to treatment with TNF-α was observed. Interestingly, we noticed a significant increase in TNF-α-induced luciferase activity when the SRC-3^KO cells were co-transfected with an expression vector encoding wild type SRC-3 (Fig. 8A). Of note, this SRC-3 mediated increase in luciferase activity was not observed when the SRC-3^KO cells were co-transfected with a vector encoding the mutated SRC-3 S857A (Fig. 8A). This result shows that phosphorylation of SRC-3 at S857 is required for the ability of SRC-3 to co-activate NF-κB in response to TNF-α in A549 cells. Furthermore, knockdown of SRC-3 expression by specific siRNA or inhibition of MK2 activity with the inhibitor PF-3644022 both resulted in significant decrease in NF-κB-driven luciferase activity in response to treatment with TNF-α (Fig. 8B) (Supplementary Fig. S1B). These findings strongly indicate that both SRC-3 and MK2 activity are required for the induction of NF-κB-dependent transcription in response to TNF-α. Interleukin-6 (IL-6) is a well-known downstream target of NF-κB³³. Earlier studies have shown that the phosphorylation of SRC-3 at S857 is necessary for the TNF-α stimulated IL-6 mRNA expression²⁰. When SRC-3^WT and SRC-3^KO A549 cells were stimulated with TNF-α, the TNF-α-induced IL-6 mRNA expression was significantly lower in the SRC-3^KO compared to the SRC-3^WT A549 cells (Fig. 8C). This indicates a role of SRC-3 in IL-6 mRNA expression. MMP9 is another known downstream target of NF-κB³⁴. When SRC-3^WT and SRC-3^KO A549 cells were stimulated with TNF-α, MMP9 mRNA expression increased substantially in both cell lines. There was however, no significant difference in the increase of MMP9 mRNA expression between SRC-3^WT and SRC-3^KO cell lines stimulated with TNF-α (Fig. 8D). These results indicate that although the expression of both IL-6 and MMP9 mRNA are induced by TNF-α only IL-6 expression is specifically dependent on SRC-3.

As MK2 was shown to be involved in NF-κB-dependent transcription (Fig. 8B), we performed experiments to investigate the role of MK2 in TNF-α stimulated IL-6 transcription in lung cancer cells. We transfected A549 cells with an IL-6 promoter-dependent luciferase vector. The cells were then stimulated with TNF-α after pretreatment with either the MK2 inhibitor PF-3644022, or DMSO as control. TNF-α-induced luciferase activity decreased significantly when MK2 activity was inhibited, suggesting involvement of MK2 activity in IL-6 transcription (Fig. 8E). Furthermore, we studied the role of MK2 in transcription of other NF-κB target genes namely, TNF receptor-associated factor 1 (TRAF1)³⁵, IL-8³⁶ and Intercellular Adhesion Molecule 1 (ICAM1)³⁷. A549 cells pretreated with DMSO or PF-3644022 for 30 min were stimulated with TNF-α for 5 h or left untreated. We found that mRNA expression of TRAF1 (Fig. 8F), IL-8 (Fig. 8G) and ICAM1 (Fig. 8H) increased significantly when stimulated with TNF-α compared to control. However, when MK2 activity was inhibited there was a significant decrease in mRNA expression of TRAF1 and IL-8 but not ICAM1. This indicates that MK2 is involved in regulation of selective NF-κB target genes.

As p38^MAPK is an upstream activator of MK2 and SRC-3, we examined the role of p38^MAPK in NF-κB mediated transcription. First, we determined the role of p38^MAPK in NF-κB-dependent luciferase activity. The significant increase in TNF-α-induced NF-κB luciferase activity in A549-NF-κB-Luc cell decreased significantly when inhibited with SB-202190 (Fig. 8I). This suggests that p38^MAPK is involved in transcriptional activity of NF-κB. Next, we analyzed the involvement of p38^MAPK in TNF-α-stimulated IL-6 transcription in A549 cells. The TNF-α-induced increase in IL-6 transcription activity was significantly decreased when p38^MAPK activity was inhibited (Fig. 8J). Furthermore, TNF-α-induced upregulation of mRNA expression of NF-κB target genes IL-6 (Fig. 8K), IL-8 (Fig. 8L) and MMP9 (Fig. 8M) were significantly inhibited when the p38^MAPK activity was inhibited in A549 cells. This confirmed the role of p38^MAPK in regulation of NF-κB target genes that are upregulated by TNF-α.

Discussion

Although SRC-3 was first described as coactivator for nuclear receptors, it turned out that it can also act as coactivator for several other transcription factors, including PEA3³, AP-1⁵, TEAD4³⁸ and NF-κB⁶. A concept has emerged which indicates that SRC-3 can act as an integrator able to connect the activation of protein kinase signaling cascades to the control of specific transcriptional programs³⁹. This integration is controlled by specific kinases that phosphorylate SRC-3 at distinct sites. These phosphorylations may form a code that determine the ability of SRC-3 to be recruited to different transcription factors. The most frequent reported phosphorylation site of SRC-3 is S857²². In the present study, we identified MK2 as the kinase responsible for both the basal, and the stress-induced phosphorylation of SRC-3 at S857 in a wide variety of cell types. This suggests that SRC-3 could be crucial for the control of various transcriptional programs via the p38^MAPK-MK2-SRC-3-S857 signaling axis.

Earlier studies suggested that SRC-3-S857 is a substrate of the atypical MAPK ERK3^3,40. Unexpectedly, we observe in our study that recombinant ERK3 was not able to efficiently phosphorylate this site of SRC-3 in in vitro kinase assays. The main difference between our in vitro kinase assays and the previous studies was the source of the ERK3 protein. In the present study, we have used recombinant ERK3 purified from insect cells, while the previous studies used immunoprecipitated HA-tagged ERK3 protein transiently expressed in HEK 293 cells. For ERK3 from mammalian cells, it is well known that it forms strong and stable complexes with the protein kinase MK5^25,41,42. Furthermore, this complex formation between ERK3 and MK5 is dependent on ERK3 phosphorylation at Serine 189. In this complex, MK5 becomes activated by ERK3, and this activation is dependent on the kinase activity of ERK3^25,41,43. In our study, we observed that S857 of SRC-3 is a bona fide substrate of MK5 in vitro, which may suggest that the kinase activity observed with HA-tagged ERK3 immunoprecipitated from HEK 293 could be due to co-precipitation of MK5. This hypothesis is further supported by the observation that MK5 is active in complex with ERK3, while MK5 is inactive in complex with kinase deficient ERK3^3,40. Moreover, it was further supported by the observation that a functional S189 in ERK3 is required for phosphorylation of SRC-3 when ERK3 was immunoprecipitated from HEK 293 cells and used in an in vitro kinase assay. These findings strengthen the assumption that MK5 co-precipitating with ERK3 is the kinase responsible for SRC-3 phosphorylation observed in these studies⁴⁰.

When examining the sequence surrounding S857 in SRC-3 (YNRAVSL) it became clear that this sequence more closely resembled the consensus for efficient phosphorylation by MK2 which is HydXRXXSX (where Hyd is a bulky hydrophobic residue), than a phosphorylation site for a proline-directed MAPK^44,45. In agreement with the MAPKAPK substrate consensus sequence, we found that S857 of SRC-3 was efficiently phosphorylated by both MAPKAPK, MK2 and MK5, but not by MAP kinases in vitro. Using a phospho-specific antibody in combination with specific siRNAs and protein kinase inhibitors together with cells derived from mice deficient for MK2 and MK3 expression, we found that S857 is phosphorylated by MK2 in response to activation of the p38^MAPK signaling pathway in several human cancer cells, as well as in mouse embryonal fibroblast and bone marrow derived mouse cells. The MK2 inhibitor PF-3644022 used in this study is reported to inhibit MK2, MK3 and MK5 activities⁴⁶. Besides, the mouse cell lines used for validation of the MK2 involvement in SRC-3 phosphorylation at S857, were knocked out for both MK2 and MK3. Therefore, we cannot completely exclude that MK3, which has a much lower expression, is also involved in the SRC-3 phosphorylation at S857 in addition to MK2.

In order to investigate the downstream targets of p38^MAPK-MK2 induced phosphorylation of SRC-3 at S857, we studied the role of SRC-3 on the transcriptional activation of NF-κB. The phosphorylation of SRC-3 at S857 was earlier described to be important for SRC-3 for complex formation with the transcription factor NF-κB, and the transcriptional activation of several cytokines including IL-6. This coactivation of NF-κB was linked to IKK-α-mediated phosphorylation of S857 in response to TNF-α stimulation⁷. We investigated the role of IKK-β and IKK-α in TNF-α-induced phosphorylation of SRC-3 at S857 in A549 cells and found that neither IKK-β nor IKK-α was involved in the phosphorylation. Besides, in all the cancer cell lines examined in the present study, we observed that pretreatment with the MK2-specific kinase inhibitor PF-3644022 efficiently blocked the phosphorylation at S857 in response to TNF-α. This finding suggests that MK2 rather than IKK-α is the major TNF-α induced kinase responsible for phosphorylation of SRC-3 at S857 in cancer cells. However, it cannot be excluded that IKK-α might be responsible for regulation of this phosphorylation in other cell types or tissues.

The p38^MAPK-MK2 signaling axis plays a prominent role in controlling cytokine expression in response to proinflammatory cytokines and cellular stress. MK2 is well known for its post-transcriptional regulation of genes harboring adenine/uridine-rich elements (AREs) in their 3ʹ-untranslated region (3ʹ-UTR), including proinflammatory genes such as IL-6, TNF-α, and IL-1β⁴⁷. Our data indicated that MK2 may also contribute to transcriptional regulation of certain cytokines such as IL-6, TRAF1 and IL-8. However, due to the profound role of MK2 in regulation of cytokine expression at the post-transcriptional level, it is difficult to exactly assess its role for the transcriptional regulation. Nonetheless, we could show that deletion of SRC-3 expression by CRISPR-Cas9 mediated gene editing significantly decreased both, basic and TNF-α induced IL-6 mRNA expression in our A549 lung cancer cell system. To further evaluate the role of MK2 in direct transcriptional activation, we employed reporter gene assays. Using a NF-κB-driven reporter assay, we could show that both SRC-3 and MK2 activity are required for full activation of the NF-κB promoter in response to TNF-α. Moreover, we also demonstrated that a functional S857 in SRC-3 is required for its ability to transactivate NF-κB in response to TNF-α. p38^MAPK was earlier described to be required for transcriptional activation of NF-κB and this activation was independent of IκB (Inhibitor of κB) phosphorylation or NF-κB translocation and DNA-binding⁴⁸. Our data support this, and suggests that the requirement for a full NF-κB-mediated transcriptional activation might be the phosphorylation of SRC-3 at S857 via the activation of the p38^MAPK-SRC-3-MK2 axis. One specific role for MK2-mediated phosphorylation of SRC-3 could be to further facilitate the TNF-α-induced nuclear translocation of SRC-3. The complete nuclear translocation of SRC-3 is efficiently blocked by pretreatment of cells with the MK2 inhibitor. The requirement for SRC-3 in co-activation of genes downstream of TNF-α could be both cell and gene specific. In our experiments, we found that SRC-3 is required for TNF-α-induced IL-6 expression while it is dispensable for TNF-α-induced MMP9 expression.

The gene encoding for SRC-3 is amplified in 5–10% of breast cancer patients, and is often found to be overexpressed on both mRNA and protein level^49,50. Together with other members of the steroid receptor coactivators, such as SRC-1 and SRC-2, SRC-3 has been shown to be important for initiation and progression of estrogen receptor (ER) positive breast cancer³⁹. Recently, Dasgupta et. al. showed that SRC-3 is important for the ability to promote tumorgenicity in both ER-dependent (MCF7 cells) and -triple negative (MDA MB 231 cells) breast cancer models²³. Knock down of SRC-3 in these models inhibited either growth (MCF-7 cells) or both growth and metastasis (MDA MB 231 cells). As these phenotypes could not be rescued by expression of the phosphorylation-defective S857A mutant of SRC-3, these results suggest that the phosphorylation of SRC-3 at S857 might be crucial for breast cancer progression.

Since the present study demonstrates that MK2 is responsible for phosphorylation of SRC-3 at S857 in a wide variety of cell lines, including triple negative breast cancer cells (MDA MB 231 cells), the results indicate that the p38^MAPK-MK2-SRC-3 signaling axis could be a relevant therapeutic target in treatment of breast cancer.

Methods

Reagents

Penicillin/streptomycin (#P0781), DMSO (#472301), anisomycin (# A5862), LPS, Sodium arsenite, PF-3644022 (#PZ0188) were purchased from Sigma-Aldrich, MO, USA. SB-202190 (#BML-EI294-001), PD-184352 (#ALX-270-471) were purchased from Alexis Biochemicals, CA, USA. Recombinant human TNF-α (#300-01A) was purchased from PeproTech, NJ, USA. Lambda phosphatase was purchased from New England Biolabs, MA, USA, BI-605906 was purchased from R&D systems, UK.

Generation of vectors

The mammalian expression vectors for expression of SRC-3 wild type (WT)-FLAG and SRC-3 S857A-FLAG as well as the vectors for expression of GST-CID-SRC-3 WT and GST-CID-SRC-3 S857A were kind gifts from Dr. Weiwen Long, Baylor College of Medicine, Texas, USA and are described in³. The expression vectors expressing siRNA resistant SRC-3 wild type (WT)-FLAG and SRC-3 S857A-FLAG were generated with quick-change mutagenesis (ThermoFisher Scientific, MA, USA) using the primers SRC-3siRF and SRC-3siRR (listed in Table 2) to introduce four silent mutations in the binding sequence for siRNA. The luciferase reporter vector κB-ConA-luc containing the binding site for NF-κB was kindly provided by Dr. Estelle Sontag, University of Texas South Western Medical Center, Texas, USA and is described in⁵¹. The plasmids PX458 (Addgene # 48138) and eSpCas9 (1.1) (Addgene # 71814) were a kind gift from Dr. Feng Zhang (MIT). To generate vector PX458 (1.1) for delivery of a Cas9 enzyme with less of target activity as described by Slaymaker et. al. the 2,281 base pair (bp) ApaI-BsmI fragment of the plasmid PX458⁵² was exchanged with corresponding fragment derived from the plasmid eSpCas9 (1.1)⁵³. The reporter gene vector pGL3-IL-6-promoter was generated by cloning of a 1,136 bp KpnI-Hind III fragment, containing the IL-6 promoter (1,186 bp) amplified from human genomic DNA by PCR using the primers IL-6-prom F and IL-6-prom R (listed in Table 2), into the vector pGL3-basic (Promega, WI, USA) linearized with the restriction sites KpnI and Hind III.

Cell lines, siRNA and transfection

MDA MB 231 (American Type Culture Collection (ATCC) Virginia, USA, HTB-26), H1299 (ATCC CRL-580), A549 (ATCC CCL-185), HeLa (ATCC CCL-2), HEK 293 (ATCC CRL-11268), Mouse Embryonic Fibroblast (MEF) and Balb/c mouse bone marrow derived dendritic cells (BMDC) cells were maintained in Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich (D 5796)) supplemented with 10% fetal bovine serum (FBS) (Millipore, MA, USA, TMS-013-B), penicillin (100 units/ml) and streptomycin (100 mg/ml) in a humidified 5% CO₂ atmosphere at 37 °C. Cell lines were authenticated by comparing DNA profiles of the cell lines with the reference cell lines. Cell lines were routinely screened for mycoplasma and mycoplasma-free cells were used for all the experiments. Generation of MK2/3 KO and rescue MEF and BMDC cells are explained in²⁷. The A549-NF-κB-Luc cells (RC0002) were obtained from Panomics San Diego, CA, USA. These cells are stably transfected with a luciferase reporter gene, which is under the transcriptional control of NF-κB.

siRNA against target genes were transfected into A549 and H1299 with Lipofectamine 2,000 or 3,000 (Invitrogen, CA, USA) prepared in OptiMEM (ThermoFisher Scientific) according to the manufacturer's instructions. Scrambled siRNA was used as control. The siRNA duplexes were purchased from ThermoFisher Scientific and are listed in Table 2. In each well of a 6-well plate, 3 × 10⁵ cells were seeded and left overnight in incubator, then the cells were transfected with 20 ng/ml target siRNA or scrambled siRNA. The cells were lysed and lysates were harvested after 48 h. Successful knockdown was verified by Western-blotting analysis using antibodies listed in Table 1. Vectors were transfected into HeLa cells with Lipofectamine 2,000 or 3,000 (ThermoFisher Scientific), into A549 and H1299 with Lipofectamine LTX plus (ThermoFisher Scientific) and into HEK 293 cells with Trans IT-LT1 reagent (Mirus, WI, USA) according to the manufacturer's instructions.

Table 1 List of antibodies.

Full size table

SRC-3 knock out by CRISPR-Cas9

Oligos for guide RNAs targeting SRC-3 were determined using the chopchop.cbu.uib.no database⁵⁴. The guide oligos (SRC-3-B) were ordered at ThermoFisher Scientific and are listed in Table 2. Guide oligos were cloned into the CRISPR-Cas9 expression vector PX458 (1.1) (Addgene #48138) as described in⁵². A549 cells were sorted using BD FACSAria III (BD Biosciences, NJ, USA) 48 h after transfection and only those cells expressing GFP were seeded individually into 96 well plates. Knock out of SRC-3 was confirmed by Western-blot using Rabbit-anti-SRC-3 (5E11, Table 1). To identify indels, genomic DNA was extracted by diluting 10 × 10⁴ cells in 30 μl of 50 mM NaOH, transferred to a tube and incubated for 10 min at 95 °C. The sample was then placed on ice and 3 μl 1 M Tris pH 8.0 was added before the sample was centrifuged for 10 min at 10,000 rpm. 3 μl of the isolated genomic DNA was used to amplify the area of interest in the SCR-3 gene by PCR (30 cycles (98 °C for 5 s, 63 °C for 10 s, 72 °C for 30 s)) using Platinum SuperFi PCR Master Mix (ThermoFisher Scientific, #12358050) and SRC-3-A forward and reverse primers listed in Table 2. The PCR product was cloned into p-Zero-blunt vector (ThermoFisher Scientific, #K270040) and at least 8 individual clones were sequenced by Sanger sequencing (DNA sequencing lab, University Hospital North Norway, Tromsø, Norway) using M13 primer listed in Table 2.

Table 2 List of oligonucleotides.

Full size table

Generation of anti-P-S857-SRC-3 antibody

The anti-P-S857-SRC-3 antibody was raised in sheep and affinity purified on the appropriate antigen residues 852–862 of human SRC-3 [YNRAVS*LDSPV] by the Division of Signal Transduction Therapy, University of Dundee, Scotland, UK.

Cell staining

About 4 × 10⁴ A549 cells were seeded on fibronectin coated coverslip in 24-well plate. Cells pretreated with either 10 μM PF-3644022 (MK2 inhibitor), SB-202190 (p38^MAPK inhibitor) or 0.2 μl DMSO for 30 min were treated with 10 ng/ml TNF-α for 60 min. Then, the cells were fixed with 500 μl 4% paraformaldehyde for 20 min and permeabilized with 500 μl 100% methanol for 5 min. After that the cells were blocked in 5% BSA for 20 min at room temperature. The cells were incubated in anti-SRC-3 antibody (Cell signaling Technology #2126) for 1 h at room temperature. Immunostaining was performed using Alexa Fluor-568 conjugated with anti-rabbit antibody (Invitrogen, #A-10042) while nuclei were visualized by staining with 1 μg/ml DAPI. Images were captured using LSM 780 inverted confocal microscope (Zeiss) at 63X magnification. Images were acquired with ZEN Black ver. 2.3 (Carl Zeiss Microscopy) software and analysed with the Fiji software. At least 100 cells were studied for each group.

Luciferase reporter gene assay

For luciferase reporter gene assay, 4 × 10⁴ SRC-3^WT or SRC-3^KO A549 cells were seeded in each well of a 24-well plate and left overnight. On the other day, cells were transfected with 120 ng of κB-ConA-luc or pGL3-IL-6-pro vector along with other required expression vectors for 48 h. After necessary treatment, cells were lysed and luciferase activity was determined using Pierce Firefly Luciferase Glow Assay Kit (ThermoFisher Scientific, #16177) or Luc-Screen (ThermoFisher Scientific) according to the manufacturers` instructions. The luminescence was measured using a CLARIOstar microplate reader (BMG Labtech, Ortenberg, Germany).

Expression of GST-CID-SRC-3 in E. coli

GST fusion proteins were expressed in E. coli (BL21) as described in²⁵.

In vitro protein kinase assay

Generation of recombinant ERK3 is described in²⁵ and ERK3 specific activity was determined as described in⁵⁵ using myelin basic protein (MBP) as a substrate. Recombinant active p38α, ERK2, MK5 and MK2 were purchased from MRC PPU reagent and services, Dundee, UK. For in vitro protein kinase assay, the active kinase was incubated with wild type GST-CID-SRC-3 fusion protein (GST-CID-SRC-3 WT) or mutant GST-CID-SRC-3 fusion protein (GST-CID-SRC-3 S857A) and 60 μM ATP in 50 μl kinase buffer (50 mM Tris HCl pH 7.5, 0.1 mM EGTA, 1 mM sodium vanadate, 1 mM DTT, 10 mM Mg(CH₃COO)₂/MgCl₂). The reaction was carried out at 30 °C for 5–30 min and terminated with LDS Sample Buffer (ThermoFisher Scientific #NP0008) and Sample Reducing Agent (ThermoFisher Scientific #B0009) and finally analyzed by Western-blotting. For in vitro kinase assay using radioactive ATP, 1 μCi [ϒ³²P] ATP (Amersham, Little Chalfont, UK) was added in the ATP mix. Phosphorylated proteins were resolved by SDS-PAGE and visualized by autoradiography using the phosphorimager Fuji BAS-5000 (Fujifilm Life Science, Tokyo, Japan).

Western-blot

Total cellular extract was obtained by lysis of the cells in MKK lysis buffer (50 mM Tris/HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1% (w/v) Triton X-100, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate and 0.27 M sucrose) containing protease inhibitors cocktail tablets (Roche, Mannheim, Germany, #04693132001). The cellular lysate was centrifuged at 13,000g for 10 min at 4 °C. Protein concentration was determined using Pierce Bradford Assay Kit (ThermoFisher Scientific #23246) and was denatured by heating for 10 min at 70 °C along with LDS Sample Buffer (ThermoFisher Scientific #NP0008) and Sample Reducing Agent (ThermoFisher Scientific #B0009). For Western-blot analysis, equal amounts of protein were separated by running it on 4–12% Bis–Tris Gels (Invitrogen # NW04122BOX) for 35 min, at 200 V, 120 mA in MES SDS Running buffer (Invitrogen #NP0002-02). See Blue Plus2 Prestained Standard (Invitrogen #LC5925), Super Signal Molecular Weight protein ladder (ThermoFisher Scientific, #84785,) and MagicMark XP Western Protein Standard (Invitrogen, #LC5602) were used as molecular weight markers. Then the proteins were transferred at 30 V, 150 mA for 2 h to Odyssey nitrocellulose membranes (LI-COR Biosciences, NE, USA #926–31092) using blotting buffer (48 mM Trisbase, 384 mM glycine and 20% methanol). After that, the membrane was blocked for 1 h using Odyssey blocking buffer (PBS) (LI-COR #927-40000) followed by incubation in respective primary antibodies overnight at dilution as mentioned in Table 1 and washed thrice with 1XTBST for 15 min then incubated with IRDye secondary antibodies (LI-COR Biosciences) in 1XTBST for 1 h. The membrane was washed thrice with TBST for a total of 15 min. Finally, fluorescent images of the blots were acquired on Odyssey Sa detection system (LI-COR Biosciences).

Immunoprecipitation

For immunoprecipitation, 2 × 10⁶ H1299 cells were seeded in a 100 mm dish. The cells were lysed and centrifuged as described in Western-blot section. The lysate obtained was cleared with activated Pierce Agarose resin (ThermoFisher Scientific). 2 mg of clarified lysate was incubated with 2 μg Mouse-anti-FLAG (Sigma-Aldrich F1804) or Rabbit-anti-NCoA-3 (M-397) (Santa Cruz Biotechnology sc-9119) antibody (Table 1) overnight at 4 °C. Then 30 μl Protein G agarose (Millipore #16-266) was added to it and incubated for 60 min at 4 °C. The mixture was then transferred to spin column (Sigma-Aldrich #SC1000) and centrifuged. The spin column was washed twice with 500 µl ice cold MKK lysis buffer then with 50 mM TRIS chloride pH 7.5. The immunoprecipitated protein was eluted by heating at 70 °C for 10 min in 60 μl LDS Sample Buffer (ThermoFisher Scientific #NP0008) and Sample Reducing Agent (ThermoFisher Scientific #B0009). The denatured protein was separated by SDS PAGE, transferred and incubated with anti-SRC-3 and anti-P-S857-SRC-3 antibody as described earlier.

RNA extraction, reverse transcription, quantitative real-time PCR

Total RNA was obtained by lysing the cells with RLT Plus Buffer (Qiagen, Venlo, Netherlands #74136) supplemented with 1 M DTT (40 µl/ml) followed by extraction with RNeasy Plus Mini kit (Qiagen #74136) according to the manufacturer’s instructions. Quantity and purity were determined using NanoDrop spectrophotometer (ThermoFisher Scientific). 1 μg of total RNA was reverse transcripted to cDNA using the High capacity cDNA reverse transcription kit (ThermoFisher Scientific #4368813) supplemented with RiboLock RNase inhibitor (ThermoFisher Scientific #EO0381) (2 U/μl). Quantification of mRNA expression was determined using Light cycler 96 (Roche). Primer pairs for qRT-PCR were purchased from Sigma-Aldrich and are listed in Table 2. 2 μl cDNA was amplified for 40 cycles (95 °C for 15 s, 60 °C for 1 min) in a 20 µl Power UP SYBR green master mix (ThermoFisher Scientific #25741) containing 200 nM of each primer. The relative expression of the target gene was normalized to the average expression of the two reference genes TFRC and GAPDH using the 2^−∆∆Ct method⁵⁶.

Statistics

Values are presented as mean ± SD of at least three replicates. Data were analyzed with unpaired t-test using GraphPad prism software version 8.2.1 (CA, USA). Differences between groups were considered to be significant with P-values < 0.05.

References

Chen, H. et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90, 569–580. https://doi.org/10.1016/s0092-8674(00)80516-4 (1997).
Article CAS PubMed Google Scholar
Louie, M. C., Zou, J. X., Rabinovich, A. & Chen, H. W. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol. Cell. Biol. 24, 5157–5171. https://doi.org/10.1128/mcb.24.12.5157-5171.2004 (2004).
Article CAS PubMed PubMed Central Google Scholar
Long, W. et al. ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J. Clin. Investig. 122, 1869–1880. https://doi.org/10.1172/jci61492 (2012).
Article CAS PubMed Google Scholar
Yan, J. et al. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Can. Res. 66, 11039–11046. https://doi.org/10.1158/0008-5472.Can-06-2442 (2006).
Article CAS Google Scholar
Liu, X. et al. Tead and AP1 coordinate transcription and motility. Cell Rep. 14, 1169–1180. https://doi.org/10.1016/j.celrep.2015.12.104 (2016).
Article CAS PubMed PubMed Central Google Scholar
Werbajh, S., Nojek, I., Lanz, R. & Costas, M. A. RAC-3 is a NF-kappa B coactivator. FEBS Lett. 485, 195–199. https://doi.org/10.1016/s0014-5793(00)02223-7 (2000).
Article CAS PubMed Google Scholar
Wu, R. C. et al. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by I kappa B kinase. Mol. Cell. Biol. 22, 3549–3561. https://doi.org/10.1128/mcb.22.10.3549-3561.2002 (2002).
Article CAS PubMed PubMed Central Google Scholar
Wang, Z. et al. Regulation of somatic growth by the p160 coactivator p/CIP. Proc. Natl. Acad. Sci. USA. 97, 13549–13554. https://doi.org/10.1073/pnas.260463097 (2000).
Article ADS CAS PubMed Google Scholar
Stashi, E., York, B. & O’Malley, B. W. Steroid receptor coactivators: Servants and masters for control of systems metabolism. Trends Endocrinol. Metab. 25, 337–347. https://doi.org/10.1016/j.tem.2014.05.004 (2014).
Article CAS PubMed PubMed Central Google Scholar
Anzick, S. L. et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965–968. https://doi.org/10.1126/science.277.5328.965 (1997).
Article CAS PubMed Google Scholar
Sakaguchi, H., Fujimoto, J., Sun, W. S. & Tamaya, T. Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers. J. Steroid Biochem. Mol. Biol. 104, 237–240. https://doi.org/10.1016/j.jsbmb.2007.03.007 (2007).
Article CAS PubMed Google Scholar
Palmieri, C. et al. Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br. J. Cancer 108, 2039–2044. https://doi.org/10.1038/bjc.2013.199 (2013).
Article CAS PubMed PubMed Central Google Scholar
Geng, C. et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc. Natl. Acad. Sci. USA. 110, 6997–7002. https://doi.org/10.1073/pnas.1304502110 (2013).
Article ADS PubMed Google Scholar
Gojis, O. et al. The role of SRC-3 in human breast cancer. Nat. Rev. Clin. Oncol. 7, 83–89. https://doi.org/10.1038/nrclinonc.2009.219 (2010).
Article CAS PubMed Google Scholar
Ma, G., Ren, Y., Wang, K. & He, J. SRC-3 has a role in cancer other than as a nuclear receptor coactivator. Int. J. Biol. Sci. 7, 664–672. https://doi.org/10.7150/ijbs.7.664 (2011).
Article PubMed PubMed Central Google Scholar
Zhou, H. J. et al. SRC-3 is required for prostate cancer cell proliferation and survival. Can. Res. 65, 7976–7983. https://doi.org/10.1158/0008-5472.Can-04-4076 (2005).
Article CAS Google Scholar
Lydon, J. P. & O’Malley, B. W. Minireview: Steroid receptor coactivator-3: A multifarious coregulator in mammary gland metastasis. Endocrinology 152, 19–25. https://doi.org/10.1210/en.2010-1012 (2011).
Article CAS PubMed Google Scholar
Mc Ilroy, M., Fleming, F. J., Buggy, Y., Hill, A. D. & Young, L. S. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. Endocr. Relat. Cancer 13, 1135–1145. https://doi.org/10.1677/erc.1.01222 (2006).
Article CAS PubMed Google Scholar
Alluri, P. G., Speers, C. & Chinnaiyan, A. M. Estrogen receptor mutations and their role in breast cancer progression. Breast Cancer Res. 16, 494. https://doi.org/10.1186/s13058-014-0494-7 (2014).
Article CAS PubMed PubMed Central Google Scholar
Wu, R. C. et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol. Cell 15, 937–949. https://doi.org/10.1016/j.molcel.2004.08.019 (2004).
Article CAS PubMed Google Scholar
Wu, R. C., Feng, Q., Lonard, D. M. & O’Malley, B. W. SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell 129, 1125–1140. https://doi.org/10.1016/j.cell.2007.04.039 (2007).
Article CAS PubMed Google Scholar
Hornbeck, P. V. et al. PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512-520. https://doi.org/10.1093/nar/gku1267 (2015).
Article CAS PubMed Google Scholar
Dasgupta, S. et al. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556, 249–254. https://doi.org/10.1038/s41586-018-0018-1 (2018).
Article ADS CAS PubMed PubMed Central Google Scholar
Wang, W. et al. ERK3 promotes endothelial cell functions by upregulating SRC-3/SP1-mediated VEGFR2 expression. J. Cell. Physiol. 229, 1529–1537. https://doi.org/10.1002/jcp.24596 (2014).
Article CAS PubMed PubMed Central Google Scholar
Seternes, O. M. et al. Activation of MK5/PRAK by the atypical MAP kinase ERK3 defines a novel signal transduction pathway. EMBO J. 23, 4780–4791. https://doi.org/10.1038/sj.emboj.7600489 (2004).
Article CAS PubMed PubMed Central Google Scholar
Bardwell, L. Mechanisms of MAPK signalling specificity. Biochem. Soc. Trans. 34, 837–841. https://doi.org/10.1042/bst0340837 (2006).
Article CAS PubMed PubMed Central Google Scholar
Ronkina, N. et al. The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol. Cell. Biol. 27, 170–181. https://doi.org/10.1128/mcb.01456-06 (2007).
Article CAS PubMed Google Scholar
Stokoe, D., Engel, K., Campbell, D. G., Cohen, P. & Gaestel, M. Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins. FEBS Lett. 313, 307–313. https://doi.org/10.1016/0014-5793(92)81216-9 (1992).
Article CAS PubMed Google Scholar
29Liu, T., Zhang, L., Joo, D. & Sun, S. C. NF-kappaB signaling in inflammation. Signal Transduction Targeted Ther. 2, 10.1038/sigtrans.2017.23 (2017).
Clark, K. et al. Novel cross-talk within the IKK family controls innate immunity. Biochem. J. 434, 93–104. https://doi.org/10.1042/bj20101701 (2011).
Article CAS PubMed Google Scholar
Li, C. et al. Specific amino acid residues in the basic helix-loop-helix domain of SRC-3 are essential for its nuclear localization and proteasome-dependent turnover. Mol. Cell. Biol. 27, 1296–1308. https://doi.org/10.1128/mcb.00336-06 (2007).
Article PubMed Google Scholar
Amazit, L. et al. Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation. Mol. Cell. Biol. 27, 6913–6932. https://doi.org/10.1128/mcb.01695-06 (2007).
Article CAS PubMed PubMed Central Google Scholar
Tian, B., Nowak, D. E., Jamaluddin, M., Wang, S. & Brasier, A. R. Identification of direct genomic targets downstream of the nuclear factor-kappaB transcription factor mediating tumor necrosis factor signaling. J. Biol. Chem. 280, 17435–17448. https://doi.org/10.1074/jbc.M500437200 (2005).
Article CAS PubMed Google Scholar
Rhee, J. W. et al. NF-kappaB-dependent regulation of matrix metalloproteinase-9 gene expression by lipopolysaccharide in a macrophage cell line RAW 264.7. J. Biochem. Mol. Biol. 40, 88–94. https://doi.org/10.5483/bmbrep.2007.40.1.088 (2007).
Article CAS PubMed Google Scholar
Schwenzer, R. et al. The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-kappaB and c-Jun N-terminal kinase. J. Biol. Chem. 274, 19368–19374. https://doi.org/10.1074/jbc.274.27.19368 (1999).
Article CAS PubMed Google Scholar
Kunsch, C. & Rosen, C. A. NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol. Cell. Biol. 13, 6137–6146. https://doi.org/10.1128/mcb.13.10.6137 (1993).
Article CAS PubMed PubMed Central Google Scholar
Bunting, K. et al. Genome-wide analysis of gene expression in T cells to identify targets of the NF-kappa B transcription factor c-Rel. J. Immunol. 178, 7097–7109. https://doi.org/10.4049/jimmunol.178.11.7097 (2007).
Article CAS PubMed Google Scholar
Kushner, M. H. et al. Loss of ANCO1 repression at AIB1/YAP targets drives breast cancer progression. EMBO Rep. 21, e48741. https://doi.org/10.15252/embr.201948741 (2020).
Article CAS PubMed Google Scholar
Lonard, D. M. & O’Malley, B. W. Molecular pathways: Targeting steroid receptor coactivators in cancer. Clin. Cancer Res. 22, 5403–5407. https://doi.org/10.1158/1078-0432.Ccr-15-1958 (2016).
Article CAS PubMed PubMed Central Google Scholar
Elkhadragy, L., Alsaran, H., Morel, M. & Long, W. Activation loop phosphorylation of ERK3 is important for its kinase activity and ability to promote lung cancer cell invasiveness. J. Biol. Chem. 293, 16193–16205. https://doi.org/10.1074/jbc.RA118.003699 (2018).
Article CAS PubMed PubMed Central Google Scholar
Schumacher, S. et al. Scaffolding by ERK3 regulates MK5 in development. EMBO J. 23, 4770–4779. https://doi.org/10.1038/sj.emboj.7600467 (2004).
Article CAS PubMed PubMed Central Google Scholar
Deleris, P. et al. Activation loop phosphorylation of the atypical MAP kinases ERK3 and ERK4 is required for binding, activation and cytoplasmic relocalization of MK5. J. Cell. Physiol. 217, 778–788. https://doi.org/10.1002/jcp.21560 (2008).
Article CAS PubMed Google Scholar
Deleris, P. et al. Activation loop phosphorylation of ERK3/ERK4 by group I p21-activated kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated protein kinase 5 signaling pathway. J. Biol. Chem. 286, 6470–6478. https://doi.org/10.1074/jbc.M110.181529 (2011).
Article CAS PubMed Google Scholar
Stokoe, D., Caudwell, B., Cohen, P. T. & Cohen, P. The substrate specificity and structure of mitogen-activated protein (MAP) kinase-activated protein kinase-2. Biochem. J. 296(Pt 3), 843–849. https://doi.org/10.1042/bj2960843 (1993).
Article CAS PubMed PubMed Central Google Scholar
Manke, I. A. et al. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol. Cell 17, 37–48. https://doi.org/10.1016/j.molcel.2004.11.021 (2005).
Article CAS PubMed Google Scholar
Mourey, R. J. et al. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J. Pharmacol. Exp. Ther. 333, 797–807. https://doi.org/10.1124/jpet.110.166173 (2010).
Article CAS PubMed Google Scholar
Soni, S., Anand, P. & Padwad, Y. S. MAPKAPK2: The master regulator of RNA-binding proteins modulates transcript stability and tumor progression. J. Exp. Clin. Cancer Res. 38, 121. https://doi.org/10.1186/s13046-019-1115-1 (2019).
Article PubMed PubMed Central Google Scholar
Beyaert, R. et al. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J. 15, 1914–1923 (1996).
Article CAS Google Scholar
Bouras, T., Southey, M. C. & Venter, D. J. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Can. Res. 61, 903–907 (2001).
CAS Google Scholar
Zhao, C. et al. Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 98, 18–23. https://doi.org/10.1002/cncr.11482 (2003).
Article CAS PubMed Google Scholar
Sontag, E., Sontag, J. M. & Garcia, A. Protein phosphatase 2A is a critical regulator of protein kinase C zeta signaling targeted by SV40 small t to promote cell growth and NF-kappaB activation. EMBO J. 16, 5662–5671. https://doi.org/10.1093/emboj/16.18.5662 (1997).
Article CAS PubMed PubMed Central Google Scholar
Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308. https://doi.org/10.1038/nprot.2013.143 (2013).
Article CAS PubMed PubMed Central Google Scholar
Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84–88. https://doi.org/10.1126/science.aad5227 (2016).
Article ADS CAS PubMed Google Scholar
Labun, K. et al. CHOPCHOP v3: Expanding the CRISPR web toolbox beyond genome editing. Nucleic Acids Res. 47, W171-w174. https://doi.org/10.1093/nar/gkz365 (2019).
Article CAS PubMed PubMed Central Google Scholar
Hastie, C. J., McLauchlan, H. J. & Cohen, P. Assay of protein kinases using radiolabeled ATP: A protocol. Nat. Protoc. 1, 968–971. https://doi.org/10.1038/nprot.2006.149 (2006).
Article CAS PubMed Google Scholar
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402–408. https://doi.org/10.1006/meth.2001.1262 (2001).
Article CAS Google Scholar
Cargnello, M. & Roux, P. P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75, 50–83. https://doi.org/10.1128/mmbr.00031-10 (2011).
Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

The authors are grateful to Stepen M. Keyse (Ninewells Hospital& Medical School, Dundee, UK) for critical reading of the manuscript. We thank Ellen Tømte and Eslaem Almahi for contributing to the early stage of this study. A.S. was funded by a PhD scholarship from UiT The Arctic University of Norway. O.M.S. is supported by the Norwegian Cancer Society (grant 198119-2019) and Northern Norway Regional Health Authority/Helse Nord RHF (project SFP1170-14 and HNF1547-20). The publication charges for this article have been funded by a grant from the publication fund of UiT The Arctic University of Norway.

Author information

Authors and Affiliations

Department of Pharmacy, UiT The Arctic University of Norway, 9037, Tromsø, Norway
Anup Shrestha, Henrike Bruckmueller, Hanne Kildalsen, Gurjit Kaur, Hilde Ljones Wetting, Ingvild Mikkola & Ole-Morten Seternes
Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, 24105, Kiel, Germany
Henrike Bruckmueller
Institute of Cell Biochemistry, Center of Biochemistry, Hannover Medical School, 30625, Hannover, Germany
Matthias Gaestel

Authors

Anup Shrestha
View author publications
You can also search for this author in PubMed Google Scholar
Henrike Bruckmueller
View author publications
You can also search for this author in PubMed Google Scholar
Hanne Kildalsen
View author publications
You can also search for this author in PubMed Google Scholar
Gurjit Kaur
View author publications
You can also search for this author in PubMed Google Scholar
Matthias Gaestel
View author publications
You can also search for this author in PubMed Google Scholar
Hilde Ljones Wetting
View author publications
You can also search for this author in PubMed Google Scholar
Ingvild Mikkola
View author publications
You can also search for this author in PubMed Google Scholar
Ole-Morten Seternes
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

H.B., I.M., H.L.W. and O.-M.S. planned the experiments; A.S., H.K., G.K., H.L.W., H.B. and O.-M.S. performed the experiments and analyzed the data; M.G. provided MK2/3 knock out (KO) MEF and BMDC cells lines, A.S., H.B., I.M., M.G., H.L.W. and O.-M.S. wrote the manuscript; H.B., I.M., H.L.W. and O.-M.S. supervised; O.-M.S. conceptualization; O.-M.S. funding acquisition; O.-M.S. project administration. All authors reviewed and approved the manuscript.

Corresponding author

Correspondence to Ole-Morten Seternes.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Shrestha, A., Bruckmueller, H., Kildalsen, H. et al. Phosphorylation of steroid receptor coactivator-3 (SRC-3) at serine 857 is regulated by the p38^MAPK-MK2 axis and affects NF-κB-mediated transcription. Sci Rep 10, 11388 (2020). https://doi.org/10.1038/s41598-020-68219-4

Download citation

Received: 29 February 2020
Accepted: 16 June 2020
Published: 09 July 2020
DOI: https://doi.org/10.1038/s41598-020-68219-4

This article is cited by

From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
- Zesi Liu
- Chunli Jing
- Fandou Kong
Journal of Ovarian Research (2024)
Mechanism of bufalin inhibition of colon cancer liver metastasis by regulating M2-type polarization of Kupffer cells induced by highly metastatic colon cancer cells
- Donghao Tang
- Haijing Wang
- Jinbao Chen
Apoptosis (2024)
Transcriptional Profiles Reveal Deregulation of Lipid Metabolism and Inflammatory Pathways in Neurons Exposed to Palmitic Acid
- M. Flores-León
- N. Alcaraz
- Rodrigo González-Barrios
Molecular Neurobiology (2021)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.